Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP-sensitive potassium (KATP) channels containing the Sulfonylurea receptor 2 (SUR2) subunit are hetero-octameric protein complexes that function as metabolic sensors, coupling cellular energy levels to membrane potential [1]. These channels consist of four pore-forming subunits (typically Kir6.1 or Kir6.2) and four regulatory SUR2 subunits encoded by the ABCC9 gene [2]. SUR2 is expressed in two major isoforms: SUR2A, found primarily in cardiac and skeletal muscle, and SUR2B, found in vascular and non-vascular smooth muscle [4]. When intracellular ATP levels drop or ADP levels rise, these channels open, causing potassium efflux and membrane hyperpolarization, which leads to smooth muscle relaxation and vasodilation [3]. Clinically, SUR2-containing channels are targeted by potassium channel openers like minoxidil for hypertension and nicorandil for angina [3]. Mutations in the ABCC9 gene are linked to Cantu syndrome, characterized by hypertrichosis and cardiovascular abnormalities, as well as certain forms of cardiomyopathy [2]. The channel's ability to protect the myocardium during ischemia makes it a significant target for cardioprotective drug development [4]. Conversely, inhibition of these channels by sulfonylureas like glibenclamide can affect vascular tone and cardiac response to stress [1].
Potassium channel openers (KCOs) bind to the SUR2 regulatory subunit, which facilitates the opening of the Kir6.x pore [3]. This results in an increase in potassium conductance, leading to hyperpolarization of the plasma membrane [4]. In vascular smooth muscle, this hyperpolarization closes voltage-gated calcium channels, reducing calcium influx and causing vasodilation [3].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-sensitive potassium channel containing Sulfonylurea receptor 2 (SUR2) (KATP (SUR2)).